Header
At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. As a global company, we have a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.

Novartis ESG Investor Day 2021

At its eighth annual ESG investor event, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical standards.

Read the Media Release

769m

Patients reached

155

Countries where Novartis products are sold

-6.5bn

Environmental impact (USD) of our activities

219bn

Social impact (USD) of our products*


Building Trust with Society

Building trust with society is a key pillar of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. It defines our approach to managing our key environmental, social and governance (ESG) topics and risks: being part of the solution on pricing and access, addressing global health challenges, being a responsible citizen, and holding ourselves to high ethical standards. Our ESG efforts are fully integrated across the company and are key to driving long-term value for our stakeholders.

We believe a focus on our material ESG topics, coupled with our inspired, curious and unbossed culture will drive better performance.  ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Annual Reporting Suite, which includes the Novartis in Society ESG Report, as well as our other Publications.

Doing the right thing is good business

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

Read More

We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, diversity and inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.


 

Materiality Assessment and Impact Valuation

Our ESG priorities are defined by our materiality assessment, it helps us understand what matters to our stakeholders and how they perceive our impact

Learn More about our materiality assessment

Corporate Governance

Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.


Novartis in Society ESG Report

The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and building trust with society.

Learn More

Environmental, Social and Governance (ESG) Index

Novartis aims to report comprehensively and transparently about ESG topics. We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. 

Learn More

* Based on 54 Innovative Medicines brands and 40 Sandoz products in 132 countries